Characterization of an MDR1 retroviral bicistronic vector for correction of X-linked severe combined immunodeficiency

S. Kleiman,I. Pastan,J. Puck,M. Gottesman

DOI: https://doi.org/10.1038/sj.gt.3300651

1998-05-01

Gene Therapy

Abstract:

What problem does this paper attempt to address?

Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?

Marina Cavazzana,Emmanuelle Six,Chantal Lagresle-Peyrou,Isabelle André-Schmutz,Salima Hacein-Bey-Abina

DOI: https://doi.org/10.1089/hum.2015.137

2016-02-01

Human Gene Therapy

Abstract:More than 20 years ago, X-linked severe combined immunodeficiency (SCID-X1) appeared to be the best condition to test the feasibility of hematopoietic stem cell gene therapy. The seminal SCID-X1 clinical studies, based on first-generation gammaretroviral vectors, demonstrated good long-term immune reconstitution in most treated patients despite the occurrence of vector-related leukemia in a few of them. This gene therapy has successfully enabled correction of the T cell defect. Natural killer and B cell defects were only partially restored, most likely due to the absence of a conditioning regimen. The success of these pioneering trials paved the way for the extension of gene-based treatment to many other diseases of the hematopoietic system, but the unfortunate serious adverse events led to extensive investigations to define the retrovirus integration profiles. This review puts into perspective the clinical experience of gene therapy for SCID-X1, with the development and implementation of new generations of safer vectors such as self-inactivating gammaretroviral or lentiviral vectors as well as major advances in integrome knowledge.

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1

Marion G Ott,Manfred Schmidt,Kerstin Schwarzwaelder,Stefan Stein,Ulrich Siler,Ulrike Koehl,Hanno Glimm,Klaus Kühlcke,Andrea Schilz,Hana Kunkel,Sonja Naundorf,Andrea Brinkmann,Annette Deichmann,Marlene Fischer,Claudia Ball,Ingo Pilz,Cynthia Dunbar,Yang Du,Nancy A Jenkins,Neal G Copeland,Ursula Lüthi,Moustapha Hassan,Adrian J Thrasher,Dieter Hoelzer,Christof von Kalle,Reinhard Seger,Manuel Grez

DOI: https://doi.org/10.1038/nm1393

IF: 82.9

2006-04-01

Nature Medicine

Abstract:Gene transfer into hematopoietic stem cells has been used successfully for correcting lymphoid but not myeloid immunodeficiencies. Here we report on two adults who received gene therapy after nonmyeloablative bone marrow conditioning for the treatment of X-linked chronic granulomatous disease (X-CGD), a primary immunodeficiency caused by a defect in the oxidative antimicrobial activity of phagocytes resulting from mutations in gp91phox. We detected substantial gene transfer in both individuals' neutrophils that lead to a large number of functionally corrected phagocytes and notable clinical improvement. Large-scale retroviral integration site–distribution analysis showed activating insertions in MDS1-EVI1, PRDM16 or SETBP1 that had influenced regulation of long-term hematopoiesis by expanding gene-corrected myelopoiesis three- to four-fold in both individuals. Although insertional influences have probably reinforced the therapeutic efficacy in this trial, our results suggest that gene therapy in combination with bone marrow conditioning can be successfully used to treat inherited diseases affecting the myeloid compartment such as CGD.

biochemistry & molecular biology,cell biology,medicine, research & experimental
CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells

Julie Brault,Taylor Liu,Siyuan Liu,Amanda Lawson,Uimook Choi,Nikita Kozhushko,Vera Bzhilyanskaya,Mara Pavel-Dinu,Ronald J. Meis,Michael A. Eckhaus,Sandra S. Burkett,Marita Bosticardo,Benjamin P. Kleinstiver,Luigi D. Notarangelo,Cicera R. Lazzarotto,Shengdar Q. Tsai,Xiaolin Wu,Gary A. Dahl,Matthew H. Porteus,Harry L. Malech,Suk See De Ravin

DOI: https://doi.org/10.3389/fimmu.2022.1067417

IF: 7.3

2023-01-04

Frontiers in Immunology

Abstract:Introduction Ex vivo gene therapy for treatment of Inborn errors of Immunity (IEIs) have demonstrated significant clinical benefit in multiple Phase I/II clinical trials. Current approaches rely on engineered retroviral vectors to randomly integrate copy(s) of gene-of-interest in autologous hematopoietic stem/progenitor cells (HSPCs) genome permanently to provide gene function in transduced HSPCs and their progenies. To circumvent concerns related to potential genotoxicities due to the random vector integrations in HSPCs, targeted correction with CRISPR-Cas9-based genome editing offers improved precision for functional correction of multiple IEIs. Methods We compare the two approaches for integration of IL2RG transgene for functional correction of HSPCs from patients with X-linked Severe Combined Immunodeficiency (SCID-X1 or XSCID); delivery via current clinical lentivector (LV)- IL2RG versus targeted insertion (TI) of IL2RG via homology-directed repair (HDR) when using an adeno-associated virus (AAV)- IL2RG donor following double-strand DNA break at the endogenous IL2RG locus. Results and discussion In vitro differentiation of LV- or TI-treated XSCID HSPCs similarly overcome differentiation block into Pre-T-I and Pre-T-II lymphocytes but we observed significantly superior development of NK cells when corrected by TI (40.7% versus 4.1%, p = 0.0099). Transplants into immunodeficient mice demonstrated robust engraftment (8.1% and 23.3% in bone marrow) for LV- and TI- IL2RG HSPCs with efficient T cell development following TI- IL2RG in all four patients’ HSPCs. Extensive specificity analysis of CRISPR-Cas9 editing with rhAmpSeq covering 82 predicted off-target sites found no evidence of indels in edited cells before ( in vitro ) or following transplant, in stark contrast to LV’s non-targeted vector integration sites. Together, the improved efficiency and safety of IL2RG correction via CRISPR-Cas9-based TI approach provides a strong rationale for a clinical trial for treatment of XSCID patients.

immunology
Correction of X-CGD patient HSPCs by targeted CYBB cDNA insertion using CRISPR/Cas9 with 53BP1 inhibition for enhanced homology-directed repair

Colin L. Sweeney,Mara Pavel-Dinu,Uimook Choi,Julie Brault,Taylor Liu,Sherry Koontz,Linhong Li,Narda Theobald,Janet Lee,Ezekiel A. Bello,Xiaolin Wu,Ronald J. Meis,Gary A. Dahl,Matthew H. Porteus,Harry L. Malech,Suk See De Ravin

DOI: https://doi.org/10.1038/s41434-021-00251-z

2021-03-12

Gene Therapy

Abstract:X-linked chronic granulomatous disease is an immunodeficiency characterized by defective production of microbicidal reactive oxygen species (ROS) by phagocytes. Causative mutations occur throughout the 13 exons and splice sites of the CYBB gene, resulting in loss of gp91phox protein. Here we report gene correction by homology-directed repair in patient hematopoietic stem/progenitor cells (HSPCs) using CRISPR/Cas9 for targeted insertion of CYBB exon 1–13 or 2–13 cDNAs from adeno-associated virus donors at endogenous CYBB exon 1 or exon 2 sites. Targeted insertion of exon 1–13 cDNA did not restore physiologic gp91phox levels, consistent with a requirement for intron 1 in CYBB expression. However, insertion of exon 2–13 cDNA fully restored gp91phox and ROS production upon phagocyte differentiation. Addition of a woodchuck hepatitis virus post-transcriptional regulatory element did not further enhance gp91phox expression in exon 2–13 corrected cells, indicating that retention of intron 1 was sufficient for optimal CYBB expression. Targeted correction was increased ~1.5-fold using i53 mRNA to transiently inhibit nonhomologous end joining. Following engraftment in NSG mice, corrected HSPCs generated phagocytes with restored gp91phox and ROS production. Our findings demonstrate the utility of tailoring donor design and targeting strategies to retain regulatory elements needed for optimal expression of the target gene.

genetics & heredity,biochemistry & molecular biology,medicine, research & experimental,biotechnology & applied microbiology
Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem/progenitor cells

Suk See De Ravin,Julie Brault,Ronald J Meis,Siyuan Liu,Linhong Li,Mara Pavel-Dinu,Cicera R Lazzarotto,Taylor Liu,Sherry M Koontz,Uimook Choi,Colin L Sweeney,Narda Theobald,GaHyun Lee,Aaron B Clark,Sandra S Burkett,Benjamin P Kleinstiver,Matthew H Porteus,Shengdar Tsai,Douglas B Kuhns,Gary A Dahl,Stephen Headey,Xiaolin Wu,Harry L Malech,Ronald J. Meis,Cicera R. Lazzarotto,Sherry M. Koontz,Colin L. Sweeney,Aaron B. Clark,Sandra S. Burkett,Benjamin P. Kleinstiver,Matthew H. Porteus,Douglas B. Kuhns,Gary A. Dahl,Harry L. Malech

DOI: https://doi.org/10.1182/blood.2020008503

IF: 20.3

2021-05-13

Blood

Abstract:Abstract Lentivector gene therapy for X-linked chronic granulomatous disease (X-CGD) has proven to be a viable approach, but random vector integration and subnormal protein production from exogenous promoters in transduced cells remain concerning for long-term safety and efficacy. A previous genome editing–based approach using Streptococcus pyogenes Cas9 mRNA and an oligodeoxynucleotide donor to repair genetic mutations showed the capability to restore physiological protein expression but lacked sufficient efficiency in quiescent CD34+ hematopoietic cells for clinical translation. Here, we report that transient inhibition of p53-binding protein 1 (53BP1) significantly increased (2.3-fold) long-term homology-directed repair to achieve highly efficient (80% gp91phox+ cells compared with healthy donor control subjects) long-term correction of X-CGD CD34+ cells.

hematology
Recombination–deletion between homologous cassettes in retrovirus is suppressed via a strategy of degenerate codon substitution

Eung Jun Im,Anthony J Bais,Wen Yang,Qiangzhong Ma,Xiuyang Guo,Steven M Sepe,Richard P Junghans,two authors contributed equally to this work

DOI: https://doi.org/10.1038/mtm.2014.22

2014-01-01

Abstract:Transduction and expression procedures in gene therapy protocols may optimally transfer more than a single gene to correct a defect and/or transmit new functions to recipient cells or organisms. This may be accomplished by transduction with two (or more) vectors, or, more efficiently, in a single vector. Occasionally, it may be useful to coexpress homologous genes or chimeric proteins with regions of shared homology. Retroviridae include the dominant vector systems for gene transfer (e.g., gamma-retro and lentiviruses) and are capable of such multigene expression. However, these same viruses are known for efficient recombination-deletion when domains are duplicated within the viral genome. This problem can be averted by resorting to two-vector strategies (two-chain two-vector), but at a penalty to cost, convenience, and efficiency. Employing a chimeric antigen receptor system as an example, we confirm that coexpression of two genes with homologous domains in a single gamma-retroviral vector (two-chain single-vector) leads to recombination-deletion between repeated sequences, excising the equivalent of one of the chimeric antigen receptors. Here, we show that a degenerate codon substitution strategy in the two-chain single-vector format efficiently suppressed intravector deletional loss with rescue of balanced gene coexpression by minimizing sequence homology between repeated domains and preserving the final protein sequence.
A Mouse Model of X-Linked Chronic Granulomatous Disease for the Development of CRISPR/Cas9 Gene Therapy

Seren Sevim-Wunderlich,Tu Dang,Jana Rossius,Frank Schnütgen,Ralf Kühn

DOI: https://doi.org/10.3390/genes15060706

IF: 4.141

2024-05-29

Genes

Abstract:Chronic granulomatous disease (CGD) is an inherited immunodeficiency disease mainly caused by mutations in the X-linked CYBB gene that abrogate reactive oxygen species (ROS) production in phagocytes and microbial defense. Gene repair using the CRISPR/Cas9 system in hematopoietic stem and progenitor cells (HSPCs) is a promising technology for therapy for CGD. To support the establishment of efficient and safe gene therapies for CGD, we generated a mouse model harboring a patient-derived mutation in the CYBB gene. Our CybbC517del mouse line shows the hallmarks of CGD and provides a source for Cybb-deficient HSPCs that can be used to evaluate gene-therapy approaches in vitro and in vivo. In a setup using Cas9 RNPs and an AAV repair vector in HSPCs, we show that the mutation can be repaired in 19% of treated cells and that treatment restores ROS production by macrophages. In conclusion, our CybbC517del mouse line provides a new platform for refining and evaluating novel gene therapies and studying X-CGD pathophysiology.

genetics & heredity
Construction and Characterization of a High-Capacity Replication-Competent Murine Cytomegalovirus Vector for Gene Delivery

André Riedl,Denisa Bojková,Jiang Tan,Ábris Jeney,Pia-Katharina Larsen,Csaba Jeney,Florian Full,Ulrich Kalinke,Zsolt Ruzsics

DOI: https://doi.org/10.3390/vaccines12070791

2024-07-18

Vaccines

Abstract:We investigated the basic characteristics of a new murine cytomegalovirus (MCMV) vector platform. Using BAC technology, we engineered replication-competent recombinant MCMVs with deletions of up to 26% of the wild-type genome. To this end, we targeted five gene blocks (m01-m17, m106-m109, m129-m141, m144-m158, and m159-m170). BACs featuring deletions from 18% to 26% of the wild-type genome exhibited delayed virus reconstitution, while smaller deletions (up to 16%) demonstrated reconstitution kinetics similar to those of the wild type. Utilizing an innovative methodology, we introduced large genomic DNA segments, up to 35 kbp, along with reporter genes into a newly designed vector with a potential cloning capacity of 46 kbp (Q4). Surprisingly, the insertion of diverse foreign DNAs alleviated the delayed plaque formation phenotype of Q4, and these large inserts remained stable through serial in vitro passages. With reporter-gene-expressing recombinant MCMVs, we successfully transduced not only mouse cell lines but also non-rodent mammalian cells, including those of human, monkey, bovine, and bat origin. Remarkably, even non-mammalian cell lines derived from chickens exhibited successful transduction.

immunology,medicine, research & experimental
Case Report: Novel Splicing Mutations in RFX5 Causing MHC Class II Deficiency

Shan Chen,Yuqing Xu,Yeqing Qian,Zhaohui Li,Minyue Dong

DOI: https://doi.org/10.3389/fgene.2022.978688

IF: 3.7

2022-01-01

Frontiers in Genetics

Abstract:Mutations of the Regulatory Factor X5 (RFX5) have been associated with the autosomal recessive major histocompatibility class II (MHC-II) deficiency, which is a severe immunodeficiency characterized by constitutive and interferon-gamma induced MHC II expression disorder and leads to the absence of cellular and humoral T-cell response to antigen challenge. The compound heterozygous splicing mutations of RFX5: c.353 + 6T>G (maternally inherited) and c.757 + 1G>A (paternally inherited) were identified in an infant diagnosed severe immunodeficiency. The mutation c.757 + 1G>A was classified as likely pathogenic while c.353 + 6T>G was classified as the variant of uncertain significance according to American College of Medical Genetics and Genomics (ACMG). To investigate the pathogenicity of RFX5: c.353 + 6T>G, reverse transcription PCR (RT-PCR) was conducted with the mother’s peripheral blood. An insertion of 191-bp intronic sequence (intron 6) was found in the transcripts, and this resulted in a frameshift and premature truncation of the protein, especially reduced the DNA-binding domain (DBD) of the RFX5 protein. Our data expanded the spectrum of pathogenic mutations in MHC-II deficiency and put new insights into the genetic counseling, prenatal diagnosis and preimplantation genetic testing (PGT) for the disease.
Biological Characteristics of Severe Combined Immunodeficient Mice Produced by CRISPR/Cas9-Mediated Rag2 and IL2rg Mutation

Yong Zhao,Peijuan Liu,Zhiqian Xin,Changhong Shi,Yinlan Bai,Xiuxuan Sun,Ya Zhao,Xiaoya Wang,Li Liu,Xuan Zhao,Zhinan Chen,Hai Zhang

DOI: https://doi.org/10.3389/fgene.2019.00401

2019-04-30

Abstract:Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas)9 is a novel and convenient gene editing system that can be used to construct genetically modified animals. Recombination activating gene 2 (Rag2) is a core component that is involved in the initiation of V(D)J recombination during T- and B-cells maturation. Separately, the interleukin-2 receptor gamma chain gene (IL2rg) encoded the protein-regulated activity of natural killer (NK) cells and shared common receptors of some cytokines. Rag2 and IL2rg mutations cause immune system disorders associated with T-, B-, and NK cell function and some cytokine activities. In the present study, 2 single-guide RNAs (sgRNAs) targeted on Rag2 and IL2rg genes were microinjected into the zygotes of BALB/c mice with Cas9 messenger RNA (mRNA) to create Rag2/IL2rg -/- double knockout mice, and the biological characteristics of the mutated mice were subsequently analyzed. The results showed that CRISPR/Cas9-induced indel mutation displaced the frameshift of Rag2 and IL2rg genes, resulting in a decrease in the number of T-, B-, and NK cells and the destruction of immune-related tissues like the thymus and spleen. Mycobacterium tuberculosis 85B antigen could not induce cellular and humoral immune response in mice. However, this aberrant immune activity compromised the growth of several tumor heterogenous grafts in the mutated mice, including orthotopic and subcutaneous transplantation tumors. Thus, Rag2/IL2rg -/- knockout mice possessed features of severe combined immunodeficiency (SCID), which is an ideal model for human xenograft.
Targeted knock-in of NCF1 cDNA into the NCF2 locus leads to myeloid phenotypic correction of p47 phox -deficient chronic granulomatous disease

Kah Mun Siow,Merve Güngör,Dominik Wrona,Federica Raimondi,Oleksandr Pastukhov,Panagiotis Tsapogas,Timon Menzi,Michael Schmitz,Péter István Kulcsár,Gerald Schwank,Ansgar Schulz,Martin Jinek,Ute Modlich,Ulrich Siler,Janine Reichenbach

DOI: https://doi.org/10.1016/j.omtn.2024.102229

2024-05-24

Abstract:p47 phox -deficient chronic granulomatous disease (p47-CGD) is a primary immunodeficiency caused by mutations in the neutrophil cytosolic factor 1 (NCF1) gene, resulting in defective NADPH oxidase function in phagocytes. Due to its complex genomic context, the NCF1 locus is not suited for safe gene editing with current genome editing technologies. Therefore, we developed a targeted NCF1 coding sequence knock-in by CRISPR-Cas9 ribonucleoprotein and viral vector template delivery, to restore p47 phox expression under the control of the endogenous NCF2 locus. NCF2 encodes for p67 phox , an NADPH oxidase subunit that closely interacts with p47 phox and is predominantly expressed in myeloid cells. This approach restored p47 phox expression and NADPH oxidase function in p47-CGD patient hematopoietic stem and progenitor cells (HSPCs) and in p47 phox -deficient mouse HSPCs, with the transgene expression following a myeloid differentiation pattern. Adeno-associated viral vectors performed favorably over integration-deficient lentiviral vectors for template delivery, with fewer off-target integrations and higher correction efficacy in HSPCs. Such myeloid-directed gene editing is promising for clinical CGD gene therapy, as it leads to the co-expression of p47 phox and p67 phox , ensuring spatiotemporal and near-physiological transgene expression in myeloid cells.
On the generation of the MSD-Ѱ class of defective HIV proviruses

Atze T. Das,Alexander O. Pasternak,Ben Berkhout

DOI: https://doi.org/10.1186/s12977-019-0481-2

2019-07-11

Retrovirology

Abstract:Antiretroviral therapy (ART) can effectively suppress ongoing HIV replication and block disease progression, but the infection is never cured due to the persistence of a small pool of latently infected cells hosting integrated replication-competent HIV proviruses. However, the vast majority of HIV proviruses in ART-treated patients are replication-incompetent due to a variety of genetic defects. Most defective proviruses (around 90%) contain large internal deletions or are G-to-A hypermutated, resulting in destruction of most if not all viral open reading frames, which is consistent with the idea that cytotoxic T cells (CTLs) effectively remove cells that produce viral antigens. An intriguing subclass of defective proviruses (around 10%) that are consistently detected in such patients carry a small deletion or a point mutation in a relatively precise and well conserved region near the 5ʹ end of the HIV genome, in the area that encodes the major splice donor (MSD) site and the packaging signal Ѱ in the viral RNA genome. Why this subclass of proviruses is defective has never been properly understood. We now propose a mechanistic scenario for how these MSD-Ѱ mutations can prevent viral protein expression. Based on ample results in literature, we argue that MSD inactivation triggers the activity of the 5ʹ-polyadenylation site, resulting in the production of ultra-short non-protein-coding HIV transcripts.

virology
High-efficiency Transduction and Correction of Murine Hemophilia B Using AAV2 Vectors Devoid of Multiple Surface-exposed Tyrosines

David M Markusic,Roland W Herzog,George V Aslanidi,Brad E Hoffman,Baozheng Li,Mengxin Li,Giridhara R. Jayandharan,Chen Ling,Irene Zolotukhin,Wenqin Ma,Sergei Zolotukhin,Arun Srivastava,Li Zhong

DOI: https://doi.org/10.1038/mt.2010.172

IF: 12.91

2010-01-01

Molecular Therapy

Abstract:Elimination of specific surface-exposed single tyrosine (Y) residues substantially improves hepatic gene transfer with adeno-associated virus type 2 (AAV2) vectors. Here, combinations of mutations in the seven potentially relevant Y residues were evaluated for further augmentation of transduction efficiency. These mutant capsids packaged viral genomes to similar titers and retained infectivity. A triple-mutant (Y444+500+730F) vector consistently had the highest level of in vivo gene transfer to murine hepatocytes, approximately threefold more efficient than the best single-mutants, and ~30-80-fold higher compared with the wild-type (WT) AAV2 capsids. Improvement of gene transfer was similar for both single-stranded AAV (ssAAV) and self-complementary AAV (scAAV) vectors, indicating that these effects are independent of viral second-strand DNA synthesis. Furthermore, Y730F and triple-mutant vectors provided a long-term therapeutic and tolerogenic expression of human factor IX (hF.IX) in hemophilia B (HB) mice after administration of a vector dose that only results in subtherapeutic and transient expression with WT AAV2 encapsidated vectors. In summary, introduction of multiple tyrosine-mutations into the AAV2 capsid results in vectors that yield at least 30-fold improvement of transgene expression, thereby lowering the required therapeutic dose and potentially vector-related immunogenicity. Such vectors should be attractive for treatment of hemophilia and other genetic diseases.
[New data on the localization and role of nucleoproteins and nucleic acids in the living cell].

R. Vendrely

Abstract:
Combination gene therapy for HIV using a conditional suicidal gene with CCR5 knockout

Tugba Mehmetoglu-Gurbuz,Rose Yeh,Himanshu Garg,Anjali Joshi

DOI: https://doi.org/10.1186/s12985-021-01501-7

IF: 5.916

2021-01-30

Virology Journal

Abstract:Abstract Background Gene therapy approaches using hematopoietic stem cells to generate an HIV resistant immune system have been shown to be successful. The deletion of HIV co-receptor CCR5 remains a viable strategy although co-receptor switching to CXCR4 remains a major pitfall. To overcome this, we designed a dual gene therapy strategy that incorporates a conditional suicide gene and CCR5 knockout (KO) to overcome the limitations of CCR5 KO alone. Methods A two-vector system was designed that included an integrating lentiviral vector that expresses a HIV Tat dependent Thymidine Kinase mutant SR39 (TK-SR39) and GFP reporter gene. The second non-integrating lentiviral (NIL) vector expresses a CCR5gRNA-CRISPR/Cas9 cassette and HIV Tat protein. Results Transduction of cells sequentially with the integrating followed by the NIL vector allows for insertion of the conditional suicide gene, KO of CCR5 and transient expression of GFP to enrich the modified cells. We used this strategy to modify TZM cells and generate a cell line that was resistant to CCR5 tropic viruses while permitting infection of CXCR4 tropic viruses which could be controlled via treatment with Ganciclovir. Conclusions Our study demonstrates proof of principle that a combination gene therapy for HIV is a viable strategy and can overcome the limitation of editing CCR5 gene alone.

virology
Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy

Alena Moiseenko,Anthony Sinadinos,Ana Sergijenko,Kyriel Pineault,Aarash Saleh,Konradin Nekola,Nathalie Strang,Anastasia Eleftheraki,A Christopher Boyd,Jane C Davies,Deborah R Gill,Stephen C Hyde,Gerry McLachlan,Tim Rath,Michael Rothe,Axel Schambach,Silke Hobbie,Michael Schuler,Udo Maier,Matthew J Thomas,Detlev Mennerich,Manfred Schmidt,Uta Griesenbach,Eric W F W Alton,Sebastian Kreuz

DOI: https://doi.org/10.1183/13993003.01683-2023

2024-08-22

Abstract:Rationale and objective: Cystic fibrosis (CF) is caused by mutations in the CF Transmembrane Conductance Regulator (CFTR) gene. CFTR modulators offer significant improvements, but approximately 10% of patients remain nonresponsive or are intolerant. This study provides an analysis of rSIV.F/HN, a lentiviral vector optimized for lung delivery, including CFTR protein expression, functional correction of CFTR defects and genomic integration site analysis in preparation for a first-in-human clinical trial. Methods: Air-liquid interface cultures of primary human bronchial epithelial cells (HBEC) from CF patients (F508del/F508del), as well as a CFTR-deficient immortalized human lung epithelial cell line mimicking Class I (CFTR-null) homozygous mutations, were used to assess transduction efficiency. Quantification methods included a novel proximity ligation assay (PLA) for CFTR protein expression. For assessment of CFTR channel activity, Ussing chamber studies were conducted. The safety profile was assessed using integration site analysis and in vitro insertional mutagenesis studies. Results: rSIV.F/HN expressed CFTR and restored CFTR-mediated chloride currents to physiological levels in primary F508del/F508del HBECs as well as in a Class I cells. In contrast, the latter could not be achieved by small-molecule CFTR modulators, underscoring the potential of gene therapy for this mutation class. Combination of rSIV.F/HN-CFTR with the potentiator ivacaftor showed a greater than additive effect. The genomic integration pattern showed no site predominance (frequency of occurrence ≤10%), and a low risk of insertional mutagenesis was observed in an in vitro immortalization assay. Conclusions: The results underscore rSIV.F/HN as a promising gene therapy vector for CF, providing a mutation-agnostic treatment option.
Novel HDAd/EBV Reprogramming Vector and Highly Efficient Ad/CRISPR-Cas Sickle Cell Disease Gene Correction

Chao Li,Lei Ding,Chiao-Wang Sun,Li-Chen Wu,Dewang Zhou,Kevin M Pawlik,Alireza Khodadadi-Jamayran,Erik Westin,Frederick D Goldman,Tim M Townes

DOI: https://doi.org/10.1038/srep30422

2016-07-27

Abstract:CRISPR/Cas enhanced correction of the sickle cell disease (SCD) genetic defect in patient-specific induced Pluripotent Stem Cells (iPSCs) provides a potential gene therapy for this debilitating disease. An advantage of this approach is that corrected iPSCs that are free of off-target modifications can be identified before differentiating the cells into hematopoietic progenitors for transplantation. In order for this approach to be practical, iPSC generation must be rapid and efficient. Therefore, we developed a novel helper-dependent adenovirus/Epstein-Barr virus (HDAd/EBV) hybrid reprogramming vector, rCLAE-R6, that delivers six reprogramming factors episomally. HDAd/EBV transduction of keratinocytes from SCD patients resulted in footprint-free iPSCs with high efficiency. Subsequently, the sickle mutation was corrected by delivering CRISPR/Cas9 with adenovirus followed by nucleoporation with a 70 nt single-stranded oligodeoxynucleotide (ssODN) correction template. Correction efficiencies of up to 67.9% (β(A)/[β(S)+β(A)]) were obtained. Whole-genome sequencing (WGS) of corrected iPSC lines demonstrated no CRISPR/Cas modifications in 1467 potential off-target sites and no modifications in tumor suppressor genes or other genes associated with pathologies. These results demonstrate that adenoviral delivery of reprogramming factors and CRISPR/Cas provides a rapid and efficient method of deriving gene-corrected, patient-specific iPSCs for therapeutic applications.
Counter-balancing X-linked hypofunction by hyperfunction ameliorates disease features in a model of Rett syndrome: implications for genetic therapies

Christopher M McGraw,Sirena Soriano,Hao Shuang,Daniel R Connolly,Ali Chahrour,Zhenyu Wu,Agnes J Liang,Yaling Sun,Jianrong Tang,Rodney C Samaco

DOI: https://doi.org/10.1101/2024.01.18.576265

2024-01-20

Abstract:Treating monogenic neurodevelopmental disorders remains challenging and mostly symptomatic. X-linked disorders affecting women such as the postnatal neurodevelopmental disorder Rett syndrome (caused by mutations in the gene ) have additional challenges due to dosage sensitivity and to cellular mosaicism caused by random X-chromosome inactivation. An approach to augment expression from wild-type cells in RTT may be feasible and simpler than gene replacement but has never been tested due to known toxicity of over-expression, as evidenced by the distinct neurological condition known as Duplication Syndrome. Here, using genetic techniques, we find that “counter-balancing” -null cells in female -null/+ mice by a complementary population of cells harboring an X-linked transgene associated with 3X normal levels of leads to normalization of multiple whole animal phenotypic outcomes without noticeable toxicity. In addition, LFP recordings demonstrate that counter-balancing loss-of-function improves select within-region and between-region abnormalities. By comparing the counter-balance approach with an approach based on cell autonomous restoration of MeCP2 using an autosomal transgene expressing 2X normal levels of in all cells (mimicking gene replacement), we identify neurobehavioral and electrographic features best suited for preclinical biomarkers of a therapeutic response to cell autonomous versus non-cell autonomous correction. Notably, these proof-of-concept findings demonstrate how non-cell autonomous suppression of MeCP2 deficiency by boosting overall wild-type MeCP2 levels may be a viable disease-modifying therapy for RTT, with potential implications for genetic-based therapies of monogenic X-linked disorders.

Neuroscience
CRISPR-targeted MAGT1 insertion restores XMEN patient hematopoietic stem cells and lymphocytes

Julie Brault,Taylor Liu,Ezekiel Bello,Siyuan Liu,Colin L Sweeney,Ronald J Meis,Sherry Koontz,Cristina Corsino,Uimook Choi,Guillaume Vayssiere,Marita Bosticardo,Kennichi Dowdell,Cicera R Lazzarotto,Aaron B Clark,Luigi D Notarangelo,Juan C Ravell,Michael J Lenardo,Benjamin P Kleinstiver,Shengdar Q Tsai,Xiaolin Wu,Gary A Dahl,Harry L Malech,Suk See De Ravin,Colin L. Sweeney,Ronald J. Meis,Cicera R. Lazzarotto,Aaron B. Clark,Luigi D. Notarangelo,Juan C. Ravell,Michael J. Lenardo,Benjamin P. Kleinstiver,Shengdar Q. Tsai,Gary A. Dahl,Harry L. Malech

DOI: https://doi.org/10.1182/blood.2021011192

IF: 20.3

2021-12-30

Blood

Abstract:Abstract XMEN disease, defined as “X-linked MAGT1 deficiency with increased susceptibility to Epstein-Barr virus infection and N-linked glycosylation defect,” is a recently described primary immunodeficiency marked by defective T cells and natural killer (NK) cells. Unfortunately, a potentially curative hematopoietic stem cell transplantation is associated with high mortality rates. We sought to develop an ex vivo targeted gene therapy approach for patients with XMEN using a CRISPR/Cas9 adeno-associated vector (AAV) to insert a therapeutic MAGT1 gene at the constitutive locus under the regulation of the endogenous promoter. Clinical translation of CRISPR/Cas9 AAV-targeted gene editing (GE) is hampered by low engraftable gene-edited hematopoietic stem and progenitor cells (HSPCs). Here, we optimized GE conditions by transient enhancement of homology-directed repair while suppressing AAV-associated DNA damage response to achieve highly efficient (>60%) genetic correction in engrafting XMEN HSPCs in transplanted mice. Restored MAGT1 glycosylation function in human NK and CD8+ T cells restored NK group 2 member D (NKG2D) expression and function in XMEN lymphocytes for potential treatment of infections, and it corrected HSPCs for long-term gene therapy, thus offering 2 efficient therapeutic options for XMEN poised for clinical translation.

hematology
Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing

Yi-Li Min,Francesco Chemello,Hui Li,Cristina Rodriguez-Caycedo,Efrain Sanchez-Ortiz,Alex A Mireault,John R McAnally,John M Shelton,Yu Zhang,Rhonda Bassel-Duby,Eric N Olson,Alex A. Mireault,John R. McAnally,John M. Shelton,Eric N. Olson

DOI: https://doi.org/10.1016/j.ymthe.2020.05.024

IF: 12.91

2020-09-01

Molecular Therapy

Abstract:Duchenne muscular dystrophy (DMD), one of the most common neuromuscular disorders of children, is caused by the absence of dystrophin protein in striated muscle. Deletions of exons 43, 45 and 52 represent mutational "hot spot" regions in the dystrophin gene. We created three new DMD mouse models harboring deletions of exons 43, 45 or 52 to represent common DMD mutations. To optimize CRISPR/Cas9 genome editing using the single-cut strategy, we identified single guide RNAs (sgRNAs) capable of restoring dystrophin expression by inducing exon skipping and reframing. Intramuscular delivery of AAV9 encoding SpCas9 and selected sgRNAs efficiently restored dystrophin expression in these new mouse models, offering a platform for future studies of dystrophin gene correction therapies. To validate the therapeutic potential of this approach, we identified sgRNAs capable of restoring dystrophin expression by the single-cut strategy in cardiomyocytes derived from human induced pluripotent stem cells (iPSCs) with each of these hot spot deletion mutations. We found that the potential effectiveness of individual sgRNAs in correction of DMD mutations cannot be predicted a priori, highlighting the importance of sgRNA design and testing as a prelude for applying gene editing as a therapeutic strategy for DMD.

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology

Characterization of an MDR1 retroviral bicistronic vector for correction of X-linked severe combined immunodeficiency

Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?

Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1

CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells

Correction of X-CGD patient HSPCs by targeted CYBB cDNA insertion using CRISPR/Cas9 with 53BP1 inhibition for enhanced homology-directed repair

Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem/progenitor cells

Recombination–deletion between homologous cassettes in retrovirus is suppressed via a strategy of degenerate codon substitution

A Mouse Model of X-Linked Chronic Granulomatous Disease for the Development of CRISPR/Cas9 Gene Therapy

Construction and Characterization of a High-Capacity Replication-Competent Murine Cytomegalovirus Vector for Gene Delivery

Case Report: Novel Splicing Mutations in RFX5 Causing MHC Class II Deficiency

Biological Characteristics of Severe Combined Immunodeficient Mice Produced by CRISPR/Cas9-Mediated Rag2 and IL2rg Mutation

Targeted knock-in of NCF1 cDNA into the NCF2 locus leads to myeloid phenotypic correction of p47 phox -deficient chronic granulomatous disease

On the generation of the MSD-Ѱ class of defective HIV proviruses

High-efficiency Transduction and Correction of Murine Hemophilia B Using AAV2 Vectors Devoid of Multiple Surface-exposed Tyrosines

[New data on the localization and role of nucleoproteins and nucleic acids in the living cell].

Combination gene therapy for HIV using a conditional suicidal gene with CCR5 knockout

Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy

Novel HDAd/EBV Reprogramming Vector and Highly Efficient Ad/CRISPR-Cas Sickle Cell Disease Gene Correction

Counter-balancing X-linked hypofunction by hyperfunction ameliorates disease features in a model of Rett syndrome: implications for genetic therapies

CRISPR-targeted MAGT1 insertion restores XMEN patient hematopoietic stem cells and lymphocytes

Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing